4OR

(S)-N-(tert-butyl)-3-((2-chloro-5-ethyl-8-fluoro-dibenzodiazepin-11-yl)amino)pyrrolidine-1-carboxamide

Created:	2015-04-29
Last modified:	2015-06-24

Find Related PDB Entry
1 entries where 4OR is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	61
Chiral Atom Count	1
Bond Count	64
Aromatic Bond Count	12

2D diagram of 4OR

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(S)-N-(tert-butyl)-3-((2-chloro-5-ethyl-8-fluoro-dibenzodiazepin-11-yl)amino)pyrrolidine-1-carboxamide
Systematic Name (OpenEye OEToolkits)	(3S)-N-tert-butyl-3-[(8-chloranyl-11-ethyl-3-fluoranyl-benzo[b][1,4]benzodiazepin-6-yl)amino]pyrrolidine-1-carboxamide
Formula	C₂₄ H₂₉ Cl F N₅ O
Molecular Weight	457.971
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	C(C)N3c1ccc(cc1N=C(c2c3ccc(c2)Cl)NC4CN(CC4)C(=O)NC(C)(C)C)F
SMILES	CACTVS	3.385	CCN1c2ccc(F)cc2N=C(N[CH]3CCN(C3)C(=O)NC(C)(C)C)c4cc(Cl)ccc14
SMILES	OpenEye OEToolkits	1.9.2	CCN1c2ccc(cc2C(=Nc3c1ccc(c3)F)NC4CCN(C4)C(=O)NC(C)(C)C)Cl
Canonical SMILES	CACTVS	3.385	CCN1c2ccc(F)cc2N=C(N[C@H]3CCN(C3)C(=O)NC(C)(C)C)c4cc(Cl)ccc14
Canonical SMILES	OpenEye OEToolkits	1.9.2	CCN1c2ccc(cc2C(=Nc3c1ccc(c3)F)N[C@H]4CCN(C4)C(=O)NC(C)(C)C)Cl
InChI	InChI	1.03	InChI=1S/C24H29ClFN5O/c1-5-31-20-8-6-15(25)12-18(20)22(28-19-13-16(26)7-9-21(19)31)27-17-10-11-30(14-17)23(32)29-24(2,3)4/h6-9,12-13,17H,5,10-11,14H2,1-4H3,(H,27,28)(H,29,32)/t17-/m0/s1
InChIKey	InChI	1.03	NIVBGOGCJSMNMG-KRWDZBQOSA-N

Related Resource References

Resource Name	Reference
Pharos	CHEMBL3609371
PubChem	91808046, 135567021
ChEMBL	CHEMBL3609371

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.